Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 9/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 15/20 | 0.35 |
| ▸ | USP2 | O75604 | 9/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 12/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18806119 | 0.93 | TSHR (0.44) | TSHRCYP3A4USP2CYP2C19CYP2D6 | |
| SCHEMBL15132385 | 0.91 | TSHR (0.47) | TSHRCYP3A4USP2CYP2D6CYP1A2 | |
| SCHEMBL20626090 | 0.89 | TSHR (0.39) | TSHRCYP3A4USP2CYP2C19CYP2D6 | |
| SCHEMBL19083180 | 0.85 | TSHR (0.41) | TSHRCYP2D6 | |
| SCHEMBL25090130 | 0.84 | TSHR (0.38) | TSHRCYP3A4USP2CYP2C19CYP2D6 | |
| SCHEMBL20328057 | 0.84 | TSHR (0.36) | TSHRCYP3A4USP2CYP2C19CYP2D6 | |
| SCHEMBL21965097 | 0.83 | TSHR (0.42) | TSHRUSP2CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL10111450 | 0.83 | CYP2D6 (0.39) | TSHRCYP3A4USP2CYP2C19CYP2D6 | |
| SCHEMBL20153202 | 0.82 | — | — | |
| SCHEMBL18806136 | 0.82 | CYP3A4 (0.35) | TSHRCYP3A4USP2CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066029-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240066029-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2024-02-29 | — | — | US | disclosed |
| US-20210186959-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2021-06-24 | — | — | US | disclosed |
| US-10953005-B1 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3753939-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | Array Biopharma Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3523301-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-05-27 | — | — | EP | disclosed |
| US-20190183886-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2019-06-20 | — | — | US | disclosed |
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| WO-2018071447-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953005-B1 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | TSHR 1461/4885CYP3A4 3158/4885USP2 3575/4885 |
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | TSHR 1461/4885CYP3A4 3158/4885USP2 3575/4885 |
| US-20190183886-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | TSHR 1461/4885CYP3A4 3158/4885USP2 3575/4885 |
| US-20210186959-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | TSHR 1461/4885CYP3A4 3158/4885USP2 3575/4885 |
| US-20240066029-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | TSHR 1461/4885CYP3A4 3158/4885USP2 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.